Screener
AbCellera Biologics Inc. ABCL Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | December 31, 2025 | June 30, 2026 |
|---|---|---|
| Accounts payable and accrued liabilities | $25,228 | $12,107 |
| Current portion of operating lease liability | 5,815 | 5,669 |
| Payroll liabilities | 10,755 | 6,076 |
| Current portion of deferred government contribution | 8,983 | 8,632 |
| Total accounts payable and other current liabilities | $50,781 | $32,484 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s accounts payable?
- AbCellera Biologics Inc. (ABCL) reported accounts payable of $12.11M in Q2 2026.
- How has AbCellera Biologics Inc.'s accounts payable changed year-over-year?
- AbCellera Biologics Inc.'s accounts payable decreased by 62.2% year-over-year, from $32.04M to $12.11M.
- What is the long-term trend for AbCellera Biologics Inc.'s accounts payable?
- Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s accounts payable has grown at a 19.4% compound annual growth rate (CAGR), from $14.83M to $25.23M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about AbCellera Biologics Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude